食管鳞癌组织中ToPoⅡ和MRP的表达及临床意义

Expressions and significances of topoisomeraseⅡ and multidrug resistance-associated protein in human esophageal squamous cell carcinoma

目的探讨拓扑异构酶Ⅱ(ToPoⅡ)和多药耐药相关蛋白(MRP)在食管鳞癌组织中的表达及其临床意义。方法采用免疫组化方法检测69例食管鳞癌组织中ToPoⅡ和MRP的表达情况,并分析其与食管癌临床病理因素间的相关性。结果本组食管鳞癌组织中,ToPoⅡ的表达率高达94.2%(65/69),但大多患者仅表达弱阳性,占47.8%(31/65);而MRP的表达率高达63.8%(44/69);ToPoⅡ和MRP在食管鳞癌组织中表达呈正相关(r=0.311,P<0.01)。同时,ToPoⅡ和MRP表达程度与肿瘤部位、分化程度、有无淋巴结转移、TNM分期和年龄等因素均无相关性(P均>0.05)。结论检测食管鳞癌组织中ToPoⅡ和MRP表达,有助于预测肿瘤对多种化疗药物的反应程度,从而制定个性化的联合化疗方案,提高疗效。

Objective To investigate the expressions of topoisomeraseⅡ（ToPoⅡ） and multidrug resistance-associated protein （MRP） in human esophageal squamous cell carcinoma and their clinical significances. Methods The expressions of ToPoⅡ and MRP in 69 patients with esophageal squamous cell carcinoma were detected by immunohistochemical method, and their correlations with clinical pathological features were analyzed at the same time. Results The expression rate of ToPoⅡ reached to 94.2% （65/69）, in which 47.8% （31/65） was moderately positive, and MRP was 63.8% （44/69）. The expressions of ToPoⅡ and MRP were positively related （r=0.311, P〈0.01）. Meanwhile, no significant correlations were found between the expression levels of ToPoⅡ and MRP and clinical pathological features including age, tumor location, lymph node metastases and TNM stage （all P〉0.05）. Conclusion Detecting the expressions of ToPoⅡ and MRP can help to predict the sensitivity of tumor to chemotherapy drugs, personalize the therapeutic regimens and therefore improve the curative effect.